Boston continues to stand as one of the strongest ecosystems for startups in the US. The city’s unique blend of universities, investors, and industry expertise has once again proven fertile ground for innovation.
In 2025, a wide range of companies secured Series A funding to scale their ideas into market-ready solutions. This article highlights ten of these companies, ordered by the amount of capital raised, to showcase the depth and diversity of Boston’s entrepreneurial spirit.
Beamable — $13.5M
In February 2025, Beamable closed a $13.5 million Series A funding round led by BITKRAFT Ventures, with support from Advancit Capital, Solana Foundation, and others.
Beamable is redefining how developers build online games by offering decentralized backend infrastructure. Instead of relying on traditional hosting, developers can use Beamable’s platform to integrate core functions such as authentication, commerce, analytics, and Web3 capabilities through one unified API.
This approach empowers developers to focus on gameplay and storytelling while still delivering the online services that modern players expect. The funding will allow Beamable to expand its decentralized network and support more studios interested in building community-driven games.
Boston’s gaming scene has traditionally been smaller compared to other hubs, but Beamable is changing that narrative with a bold vision that merges gaming with blockchain-powered infrastructure.
The company’s success reflects a growing interest in tools that free creators from the burden of backend complexity. By positioning itself as a reliable partner for developers, Beamable is laying the foundation for Boston’s gaming ecosystem to expand in new directions.
AllSpice — $15M
AllSpice raised $15 million in June 2025, led by Rethink Impact and supported by L’ATTITUDE Ventures, DNX Ventures, and others. The company built a collaboration platform for hardware engineers inspired by GitHub.
It enables circuit designers to work on projects in real time, manage version control, and use AI-powered tools to catch errors earlier in the design process.
Hardware development often lags behind software in terms of collaboration tools. AllSpice bridges this gap by giving engineers a modern workspace that integrates automation with communication. This means fewer errors, faster design cycles, and more efficient use of engineering resources.
Boston’s strong community of robotics and hardware startups makes AllSpice’s success particularly relevant. With funding in place, the company is positioned to become a core enabler for teams designing everything from medical devices to consumer electronics.
Rhino Federated — $15M
Rhino Federated Computing, formerly Rhino Health, closed a $15 million Series A round in May 2025.
The investment, led by AlleyCorp with participation from LionBird and Qiming Ventures, supports Rhino’s federated AI platform. This technology enables organizations in regulated sectors like healthcare and finance to collaborate on AI projects without sharing raw data.
Federated learning represents a breakthrough for industries with strict privacy requirements. Instead of transferring sensitive data, organizations train models locally and share only the insights. Rhino’s platform orchestrates this process, allowing companies to collaborate safely while complying with regulations.
The approach is particularly valuable in healthcare, where patient privacy remains paramount. By enabling broader collaboration, Rhino ensures researchers and clinicians can innovate faster without compromising compliance. Boston’s reputation as a hub for healthcare innovation makes Rhino’s trajectory even more compelling.
VODA.ai — $16M
In June 2025, VODA.ai secured $16 million in Series A financing, led by CRH Ventures. The company uses artificial intelligence to help utilities manage and prioritize water infrastructure repairs. Its predictive analytics assess which pipes are most likely to fail, enabling more efficient use of limited resources.
Aging infrastructure is a challenge across the US, and Boston is no exception. VODA.ai’s technology helps utilities avoid costly emergencies by predicting failures before they occur. This not only saves money but also ensures communities have more reliable access to clean water.
The funding will support VODA.ai’s continued growth and expansion into new markets. By combining AI with practical industry needs, the company exemplifies how Boston startups turn advanced research into solutions with a tangible impact on public life.
Lynx Secures — $27M
In February 2025, Lynx raised $27 million in a Series A led by Flare Capital Partners, with strategic investments from CVS Health Ventures and McKesson Ventures.
Lynx offers an API-first platform that simplifies healthcare payments and benefits administration. Companies can embed health savings accounts, restricted spending cards, and benefit storefronts into their applications with minimal friction.
Healthcare payments have long been fragmented, leaving both patients and providers frustrated. Lynx tackles this problem by providing modern infrastructure that reduces complexity while improving transparency. Its API-driven approach resonates with insurers, employers, and financial institutions seeking to modernize their offerings.
This funding positions Lynx as a rising fintech force within Boston’s thriving healthcare ecosystem. By streamlining payments, the company reduces costs and enhances the patient experience, proving that innovation can also simplify one of the most complicated areas of healthcare.
Bluebird Kids Health — $31.5M
Bluebird Kids Health secured $31.5 million in March 2025, co-led by F-Prime Capital and .406 Ventures, with support from the Autism Impact Fund and Juxtapose. The company builds value-based pediatric clinics in underserved communities where access to care is limited.
Bluebird’s model prioritizes outcomes rather than volume, offering comprehensive physical and mental health services for children. By focusing on communities often overlooked by traditional providers, the company demonstrates how innovation can address inequities in healthcare access.
The funding will enable Bluebird to open more clinics and refine its data-driven care model. Boston’s expertise in healthcare innovation ensures the company has access to both talent and partnerships to sustain its growth. With its community-centered mission, Bluebird represents the human side of healthcare innovation.
Solu Therapeutics — $41M
Solu Therapeutics raised $41 million in April 2025 from investors including Eli Lilly, Biovision Ventures, and Pappas Capital. The company is developing therapies designed to eliminate disease-driving cells in cancers and immune disorders.
Solu’s proprietary CyTAC and TicTAC molecules pair small molecules with antibodies to selectively target and destroy harmful cells. Early results show promise in precisely eliminating malignant cells while sparing healthy ones.
This selective approach has the potential to deliver therapies with fewer side effects compared to traditional treatments.
Boston’s deep bench of biotechnology expertise supports Solu’s ambitions. With significant Series A backing, the company is preparing to advance its lead program into clinical trials while expanding its pipeline. Solu’s progress reflects the region’s ongoing strength in the life sciences.
Somite AI — $47M
Somite AI closed a $47 million Series A in May 2025, led by Khosla Ventures and supported by the Chan Zuckerberg Initiative, Fusion Fund, and others. The company is building foundation models for human cells to accelerate cell therapy development.
Its DeltaStem model uses large datasets to simulate and predict how cells behave, making it possible to produce therapeutic cell types at scale. This innovation could dramatically reduce the time and cost required to develop new treatments for chronic diseases.
Somite’s approach highlights Boston’s unique ability to merge AI with biotechnology. With the backing of high-profile investors, the company is well-positioned to push the boundaries of what TechBio can achieve.
PhaseV Lands — $50M
PhaseV secured $50 million in May 2025 in a round co-led by Accel and Insight Partners. The company’s platform leverages machine learning to optimize clinical trial design and execution. Pharmaceutical companies use PhaseV’s tools to identify suitable patients, design efficient trials, and improve overall outcomes.
The clinical trial process has long been plagued by inefficiencies. PhaseV addresses these by providing actionable insights rooted in AI. This reduces costs while increasing the likelihood of trial success, ultimately speeding new therapies to patients.
With fresh capital, PhaseV is scaling its operations to serve more pharmaceutical clients. Its work represents how Boston startups combine technology and life sciences to address systemic industry challenges.
Hillstar Bio — $67M
Hillstar Bio topped the list with a $67 million Series A in March 2025. The round included Droia Ventures, Novo Holdings, and Frazier Life Sciences. Hillstar focuses on precision immunotherapies for autoimmune diseases, targeting disease-causing cells while sparing healthy ones.
Traditional autoimmune treatments often suppress the immune system broadly, leading to unwanted side effects. Hillstar’s targeted approach promises longer-lasting relief with fewer risks. Its pipeline includes therapies for conditions such as axial spondyloarthritis, addressing unmet needs in immunology.
Boston’s dominance in biotech makes it the perfect home for Hillstar. With significant investor backing and a clear therapeutic focus, the company stands at the forefront of next-generation immunology.
A City That Continues to Build
The diversity of these Series A rounds shows Boston’s remarkable range, from decentralized gaming platforms to precision immunology. Each company demonstrates how strong ecosystems fuel innovation, blending science, technology, and entrepreneurship
For business leaders, Boston’s momentum offers a reminder of how collaboration and talent can accelerate growth. Lessons from these startups resonate far beyond Massachusetts, proving the value of combining deep research, strong capital, and supportive networks.
The city’s 2025 Series A winners are building the next wave of solutions that will reshape industries and improve lives.
Contact us to learn more about our software development services, and follow us on LinkedIn for more tech trends.
FAQ
Which Boston startup raised the largest Series A in 2025?
Hillstar Bio led the list by raising $67 million in March 2025. The company focuses on precision immunotherapies for autoimmune diseases, supported by major investors such as Droia Ventures and Novo Holdings
How are Boston startups using AI in their business models?
Several startups, including Rhino Federated Computing, Somite AI, PhaseV, and VODA.ai, use artificial intelligence to address complex challenges. Their applications range from federated learning in healthcare to foundation models for cell therapy, predictive analytics for water systems, and AI-driven clinical trial design.
Which industries saw the most funding activity in Boston’s Series A rounds?
Biotechnology and healthcare dominated, with companies like Hillstar Bio, Solu Therapeutics, Somite AI, and PhaseV raising significant amounts. Fintech (Lynx), gaming (Beamable), and hardware collaboration (AllSpice) also contributed to the city’s funding momentum.
What makes Boston a strong hub for Series A funding?
Boston’s strength comes from its mix of world-class universities, a deep talent pool, strong investor networks, and established industry clusters in biotech, healthcare, and technology. These elements combine to make the city fertile ground for early-stage innovation.
Which Boston company is transforming healthcare payments with Series A backing?
Lynx raised $27 million in February 2025 to build an API-first healthcare payments platform. Its solutions simplify benefits administration and payments for insurers, employers, and financial institutions, addressing a longstanding industry challenge.
How much total Series A funding did these ten Boston startups secure in 2025?
Together, these startups raised more than $332 million in Series A funding. This impressive figure underscores Boston’s position as one of the leading startup ecosystems in the United States.
